Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
Rhea-AI Summary
Compass Therapeutics (NASDAQ: CMPX), a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapeutics, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company will engage in a fireside chat scheduled for June 5, 2025, from 11:05 to 11:35 AM ET. The presentation will be accessible via webcast and will remain available for replay on Compass' Events page for 90 days following the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CMPX declined 0.47%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 3-5, 2025.
Fireside Chat Details
Date: Thursday, June 5, 2025
Time: 11:05 – 11:35 AM ET
Webcast Link: https://wsw.com/webcast/jeff319/cmpx/1867328
Virtual/Replay availability: The fireside chat will be archived for 90 days on Compass’ Events page.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company’s pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com
617-500-8099
FAQ
When is Compass Therapeutics (CMPX) presenting at the Jefferies Global Healthcare Conference 2025?
How long will the CMPX fireside chat replay be available?
What type of company is Compass Therapeutics (CMPX)?
Where can I watch Compass Therapeutics' (CMPX) Jefferies conference presentation?
